Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

Author： McCoy Christopher  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.3, Iss.6, 2004-11, pp. : 625-637

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis

By Frampton J.E.   Foster R.H.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 445-476

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis

By Daniel De Backer  

Drug Safety, Vol. 30, Iss. 11, 2007-01 ,pp. : 995-1010

Adis International

Access to resources Recommend Favorite

Should patients with severe sepsis receive drotrecogin alfa?

By  

Inpharma, Vol. 1, Iss. 1508, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Drotrecogin-alfa relatively cost effective in severe sepsis

By  

Inpharma, Vol. 1, Iss. 1358, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Drotrecogin alfa improves organ function in severe sepsis

By  

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite